A new research review focused on GLP-1 medications such as Ozempic confirms their established benefits: better blood sugar control, weight loss, and improved cardiovascular health. These metabolic effects are well documented and are the primary reasons the drugs are prescribed.
But the same review found little evidence that these medications also improve patients' mental health, employment prospects, marriage stability, or overall sense of well-being. That gap between physical and psychosocial outcomes is an important nuance for patients and clinicians who may assume that better health naturally translates into a better life.
The findings do not suggest the drugs are ineffective. Rather, they point to a more cautious conclusion: despite meaningful physiological improvements, the broader life effects of GLP-1 therapies may be limited. The researchers call for more attention to what these drugs can—and cannot—change.